News All News

In a recent Guppy Tank event, Professor Jeffrey Smith received feedback from a panel of investors on a new molecule that could help most sun-sensitive patients, research supported by the Blavatnik Biomedical Accelerator. Harvard's Office of Technology Development and LabCentral co-host the Guppy Tank series, where innovators pitch their early-stage concepts to a panel of entrepreneurs and investors for constructive, in-depth feedback.

A research team led by Christina Woo, professor of chemistry and chemical biology, in collaboration with a team of scientists at pharmaceutical company GSK and Scripps Research Institute, discovered a hidden binding pocket on the protein cereblon. The discovery of the allosteric cereblon binder could uncover a new area of cereblon biology to explore for cancer drugs.

Researchers in Andrew Kruse’s lab overcame a key obstacle in using the hormone relaxin as a therapy for heart disease. With support from Harvard’s Blavatnik Biomedical Accelerator, this discovery led to the launch of Tectonic Therapeutic, which is now testing its relaxin-based drug in clinical trials.

A new paper explores how stress can trigger hair loss and how our stress response can have long-term consequences for our scalps. The research may eventually yield insights into autoimmune diseases.